The U.S. government set a benchmark for COVID-19 vaccine pricing that will likely pressure other manufacturers to set similar prices, industry analysts told Reuters.
Johnson & Johnson is in talks with the government of Japan and the Bill and Melinda Gates Foundation about locking up allocations of a potential COVID-19 vaccine in advance of the company producing any of the medicines, the company’s Chief Financial Officer Joseph Wolk told Reuters in an interview.
Roche struck a $1.7 billion cancer drug pact with Blueprint Medicines, as advances in genetic testing for rare mutations drive lucrative deals for expensive treatments.
The U.S. Justice Department charged Glenmark Pharmaceuticals with conspiring with other generic drug companies to increase and hold prices for the cholesterol drug pravastatin between May 2013 and December 2015.
Gilead Sciences set the price of the only approved treatment for COVID-19, remdesivir, at $2,340 per patient for a 5-day treatment.
A federal judge dismissed a challenge by hospital groups to a federal rule requiring them to disclose prices they quietly negotiate with insurers, in a victory for White House efforts to make healthcare pricing more transparent to patients.
Twenty-six drug manufacturers were sued by the attorneys general of most U.S. states and several territories, which accused them of conspiring to reduce competition and drive up generic drug prices.
United Nations leaders called for a global effort to develop and distribute to all at affordable prices vaccines, treatments and testing kits against COVID-19.
Roche company Genentech presented one-year data from FIREFISH Part 2, a pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy (SMA).
Hector Armando Kellum, a former senior executive with the Novartis subsidiary Sandoz, pleaded guilty for his role in a price-fixing scheme for generic drugs developed by his company.
